Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Development of New Mycobacterial ATP Synthase Inhibitors

FY 2023-24

Summary
Tuberculosis (TB), one of the top infectious diseases, remains a significant global health challenge. The rise of multidrug-resistant TB necessitates the development of new therapeutics. The primary causative agent, Mycobacterium tuberculosis, relies on oxidative phosphorylation to generate adenosine triphosphate (ATP). The production of ATP is mediated by ATP synthase, using the energy created by an electrochemical gradient from the redox reactions of the mycobacterial electron transport chain. A recent approval of diarylquinoline drug, bedaquiline, for drug-resistant TB targets the mycobacterial ATP synthase. However, bedaquiline-resistant strains have been identified, requiring improved mycobacterial ATP synthase inhibitors. There is interest in better understanding the mechanism of potent inhibitors called squaramide. The lead compound, SQ31f, displayed poor pharmacokinetic properties. Recently, a computational screen of make-on-demand compounds based on SQ31f structure has been completed. However, the biochemical properties of these compounds remain unknown. Furthermore, structural determination can provide insight into the mode of action of compounds that inhibit the process of ATP synthesis. I hypothesize that the structure-activity relationship studies of mycobacterial ATP synthase inhibitors can aid the development of new antimycobacterial agents for TB. I aim to i) screen the candidate compounds; ii) investigate the selectivity and activity using biochemical assays; iii) determine the structures of inhibitor-bound mycobacterial ATP synthase using electron cryomicroscopy (cryo-EM).
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506151
Name
Kim Angelina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of New Mycobacterial ATP Synthase Inhibitors
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atp Synthase; Electron Cryomicroscopy; Tuberculosis
Abstract
Tuberculosis (TB), one of the top infectious diseases, remains a significant global health challenge. The rise of multidrug-resistant TB necessitates the development of new therapeutics. The primary causative agent, Mycobacterium tuberculosis, relies on oxidative phosphorylation to generate adenosine triphosphate (ATP). The production of ATP is mediated by ATP synthase, using the energy created by an electrochemical gradient from the redox reactions of the mycobacterial electron transport chain. A recent approval of diarylquinoline drug, bedaquiline, for drug-resistant TB targets the mycobacterial ATP synthase. However, bedaquiline-resistant strains have been identified, requiring improved mycobacterial ATP synthase inhibitors. There is interest in better understanding the mechanism of potent inhibitors called squaramide. The lead compound, SQ31f, displayed poor pharmacokinetic properties. Recently, a computational screen of make-on-demand compounds based on SQ31f structure has been completed. However, the biochemical properties of these compounds remain unknown. Furthermore, structural determination can provide insight into the mode of action of compounds that inhibit the process of ATP synthesis. I hypothesize that the structure-activity relationship studies of mycobacterial ATP synthase inhibitors can aid the development of new antimycobacterial agents for TB. I aim to i) screen the candidate compounds; ii) investigate the selectivity and activity using biochemical assays; iii) determine the structures of inhibitor-bound mycobacterial ATP synthase using electron cryomicroscopy (cryo-EM).
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kim, Angelina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~